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Abstract
Osteonecrosis of the jaw (ONJ) is a common side effect of antiresorptive drugs that are 
administered to cancer patients for bone metastasis, multiple myeloma, and osteoporo-
sis. Since both bisphosphonate (BP) and denosumab show anti-bone resorption effects 
with ONJ, antiresorptive agent-related ONJ (ARONJ) has been suggested as a com-
prehensive term encompassing both BP-related osteonecrosis of the jaw (BRONJ) and 
 denosumab-related osteonecrosis of the jaw (DRONJ). The term medication-related osteo-
necrosis of the jaw (MRONJ) is proposed as ARONJ with the antiangiogenic  inhibitors or 
molecularly targeted drugs-related ONJ. Suppression of bone remodeling may contribute 
to the development of osteonecrosis and results in inadequate osteoclast activity to allow 
healing of the extraction socket. Infection is a major factor in the  development of MRONJ. 
The major treatment goals for patients at risk of developing or who have MRONJ are pri-
oritization and support of continued oncologic treatment in patients receiving antiresorp-
tive and antiangiogenic therapy. To minimize the  development of MRONJ in patients at 
risk, regular dental examinations are encouraged. Oral hygiene should be improved and 
local infection is managed as early as possible. The use of antibiotics before and after oral 
surgical procedures has been demonstrated to lower the risk of MRONJ.
Keywords: medication-related osteonecrosis of the jaw (MRONJ), bisphosphonate (BP), 
receptor activator nuclear factor kB ligand (RANKL) inhibitor, BP-related osteonecrosis 
of the jaw (BRONJ), denosumab-related osteonecrosis of the jaw (DRONJ), antiresorptive 
agent, antiresorptive agent-related osteonecrosis of the jaw (ARONJ), angiogenesis inhibitors
1. Introduction
Osteonecrosis of the jaw is a common side effect of antiresorptive drugs that are administered 
to cancer patients for bone metastasis, multiple myeloma, and osteoporosis. Antiresorptive 
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medications contain bisphosphonates and the receptor activator nuclear factor kB ligand 
(RANKL) inhibitor [1].
On the other hand, denosumab, a human IGG2 monoclonal antibody against RANKL, is a 
therapeutic agent for bone metastasis and osteoporosis, with a half-life of approximately 
1 month. Unlike bisphosphonates (BPs), which promotes apoptosis in osteoclasts, denosumab 
inhibits osteoclastic bone resorption without causing apoptosis. Furthermore, denosumab is 
not deposited in the bone and thus does not persist for long periods of time, as is the case 
with BPs, and so the effects of denosumab are reversible [2]. However, patients treated with 
denosumab also developed ONJ (denosumab-related ONJ [DRONJ]), which was clinically 
indistinguishable from BRONJ and occurred at almost the same rates [3].
Since both BP and denosumab which show anti-bone resorption effects through  different 
molecular mechanisms of action are associated with ONJ, antiresorptive agent-related ONJ 
(ARONJ) has been suggested as a comprehensive term encompassing both BRONJ and 
DRONJ [4]. The American Association of Oral and Maxillofacial Surgeons (AAOMS) has 
 proposed the term “medication-related osteonecrosis of the jaw” (MRONJ), based on obser-
vations that antiangiogenic inhibitors and molecularly targeted drugs such as tyrosine kinase 
inhibitors are also infrequently associated with ONJ or increase the incidence of BRONJ/
DRONJ in cancer patients receiving BPs or denosumab, although global consensus has not 
yet been established [5].
The number of patients with MRONJ has grown recently. Medication-related osteonecrosis of 
the jaw (MRONJ) is defined as exposed bone in the oral cavity or extra-oral fistula in the max-
illofacial region for more than 8 weekswith the treatment of antiresorptive or antiangiogenic 
agents for more than 8 weeks. These patients have no history of radiotherapy or metastatic 
disease in the jaw. We present about the details, pathophysiology, diagnosis, staging and 
treatment, risk factor, and prevention of MRONJ in below paragraphs in this chapter.
2. Antiresorptive and antiangiogenic medications
2.1. Bisphosphonates (BPs)
Intravenous BPs are antiresorptive agents and administered for cancer–related conditions; 
hypercalcemia of malignancy, skeletal-related events (SREs) associated with bone metastases in 
the context of solid tumors (for example breast, prostate and lung cancers), and lytic lesions of 
multiple myeloma. These medications have a significant positive effect for the quality of life of 
patients with bone metastatic cancer [5]. Oral BPs are approved for the treatment of osteoporosis 
and osteopenia. They have been used in less common conditions, such as paget disease of bone 
and osteogenesis imperfection. The most common use is for osteopenia and osteoporosis [6].
2.2. RANKL inhibitor (denosumab)
The receptor activator of RANKL inhibitor (denosumab) inhibits osteoclast function and 
bone resorption. There is a decrease in the risk of vertebral, nonvertebral, and hip fractures 
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in  osteoporotic patients for administrating denosumab subcutaneously every 6 months. 
Moreover, monthly administration of denosumab is effective for decreasing SREs-related 
metastatic bone disease from solid tumors [7, 8]. In contrast to BPs, denosumab do not bind to 
bone and their effects of bone remodeling continue within 6 months [5].
2.3. Antiangiogenic medications
Angiogenesis inhibitors interfere with the formation of new blood vessels by connect-
ing to many signaling molecules and disrupting the angiogenesis-signaling cascade. These 
 medications are administered for gastrointestinal tumors, renal cell carcinoma,  neuroendocrine 
tumors, and other malignancies [5].
3. Pathophysiology
The pathophysiology of MRONJ is well unknown and considered to be multifactorial. 
Suppressed bone remodeling may contribute to the development of osteonecrosis, and in 
inadequate osteoclast activity disturbed cure the extraction socket. Infection is a major factor 
for the development of MRONJ. Bacteria stimulate bone resorption and contribute to bone 
necrosis [9].
3.1. Incidence of MRONJ
The reported incidence of MRONJ varies by study, and there are no reliable epidemiologi-
cal data derived from evidenced-based medicine. This chapter follows the data cited by the 
International Task Force on ONJ [10].
3.1.1. Patients with osteoporosis
1. BRONJ
The incidence is 1.04–69/100,000 patients per year treated with orally administered BPs 
and 0–90/100,000 patients per year treated with intravenous administration. The in-
cidence of ONJ in patients with osteoporosis treated with oral/intravenous nitrogen-
containing BPs ranges from 0.001 to 0.01%, which is estimated to be almost the same or 
slightly higher than the incidence (0.01%) of ONJ in the general population [10].
2. DRONJ
The incidence is 0–30.2/100,000 patients per year [10].
3.1.2. Cancer patients
The incidence of ONJ in cancer patients is higher than that in patients with osteoporosis. 
Prospective studies on the incidence of ONJ were conducted in cancer patients treated with 
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zoledronic acid or denosumab. Among 5723 patients with breast, prostate, and other solid 
cancer and multiple myeloma, there were 89 ONJ cases in total, 52 in the denosumab, and 
37 in the zoledronic acid-treated. The incidence in the denosumab-treated was 1.8% and 1.3% 
in the zoledronic acid [3, 11].
3.2. Uniqueness of the jaw bone [12]
There are several unique anatomical and microbiological characteristics of the jaw bone, 
which could be responsible for the specific occurrence of MRONJ. These characteristics are 
not found in bones or in other parts of the body.
The teeth erupt from the jawbone, breaking the oral epithelium, allowing infectious  factors, 
agents, and microbes in the oral cavity to directly invade the jaw bone through the gap 
between the epithelium and the teeth or via root canal.
1. The oral mucosa covering the jawbone is thin, and infection caused by mucosal injury 
spreads to the jawbone beneath the mucosa.
2. More than 800 types of resident bacteria (1011 to 1012 cm–3) inhabit dental plaque and can 
serve as a source of infection in the oral cavity.
3. Inflammation due to tooth decay, pulpitis, periapical lesions, or periodontal disease 
 extends to the jawbone.
4. The jawbone is exposed to the oral cavity following invasive dental treatments including 
tooth extraction, leading to infection.
3.3. Suppression of bone turnover
BPs and denosumab inhibit osteoclast differentiation and function, increased apoptosis, and 
decreased bone resorption and remodeling [2, 13, 14]. Osteoclast differentiation and function 
act as an effective role for bone remodeling for skeletal sites, but MRONJ occurs only pri-
marily within the alveolar bone of jaw [15]. An increased remodeling rate in the jaw may be 
considered for the differential predisposition of MRONJ to occur in the jaws compared with 
other bones in the axial or appendicular skeleton [5].
The relation between excessive suppression of C-terminal telopeptides of type I collagen 
(CTX), a bone resorption marker, and MRONJ incidence has been reported in several studies. 
However, a correlation between CTX level and severity of MRONJ has not been observed. 
There is still much controversy on whether a relationship exists between CTX levels and 
MRONJ incidence [16–18].
3.4. Infection/inflammation
The risk factors have been implicated dental disease or bacterial infection in MRONJ. Although 
dental extraction was performed in most reported cases of MRONJ, these teeth commonly 
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contracted with periodontal or periapical diseases. Inflammation or infection has long been 
considered an important component of MRONJ [19, 20].
3.5. Angiogenesis inhibition
Angiogenesis is a process that involves growth, migration, and differentiation of  endothelial 
cells to form new blood vessels. Angiogenesis favorably influences tumor growth and 
 influences tumor invasion of vessels, resulting in tumor metastasis. Osteonecrosis is 
 classically considered as an interruption in vascular supply or avascular necrosis;  therefore, 
it is not surprising that inhibition of angiogenesis is a leading hypothesis in MRONJ 
 pathophysiology [21, 22].
3.6. Soft tissue toxicity
Although BPs primarily targets the osteoclast and bind to hydroxyapatite in bone, soft tissue 
toxicity has been reported. In contrast to BPs, no soft tissue toxicity has been reported with 
denosumab [23].
4. Diagnosis of MRONJ [5, 12]
MRONJ is definitively diagnosed when the following three conditions are met:
1. Patients have a history of treatment with BP, denosumab, and antiangiogenic agents.
2. Patients have no history of radiation therapy to the jaw. Bone lesions of MRONJ must be 
differentiated from cancer metastasis to the jawbone by histological examination.
3. Exposure of alveolar bone in the oral cavity, jaw, and/or face is continuously observed for 
longer than 8 weeks after first detection by a medical or dental expert, or the bone is palpa-
ble in the intra- or extra-oral fistula for longer than 8 weeks.
5. Staging of MRONJ
The clinical manifestations and staging of MRONJ are summarized in Table 1. Paresthesia of 
the chin, including the lower lip (Vincent’s symptom), in patients treated with BP is an early 
sign of MRONJ, before alveolar bone exposure is detected [5, 12].
1. At risk
There is no apparent necrotic bone in asymptomatic patients who have been treated 
with intravenous or oral antiresorptive or antiangiogenic therapy.
Medication-Related Osteonecrosis of the Jaw
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2. Stage 0 (unexposed bone variant)
These patients have no clinical evidence of necrotic bone, but nonspecific clinical find-
ings, radiographic changes, and symptoms.
3. Stage 1
Stage 1 is defined as asymptomatic exposed and necrotic bone or a fistula that probes to 
bone. These patients have no evidence of infection and may present with radiographic 
findings localized to the alveolar bone region.
4. Stage 2 (Figures 1–4)
Stage 2 is defined as exposed and necrotic bone or a fistula that probes to bone with 
 evidence of infection. These patients are typically symptomatic. These patients also 
may present with radiographic findings which are localized to the alveolar bone region.
5. Stage 3 (Figures 5–11)
Stage 3 is defined as exposed and necrotic bone or fistula that probes to bone with evi-
dence of infection and at least one of the following:
(i) Exposed necrotic bone extending beyond the region of alveolar bone to the inferior 
border and ramus in the mandible, maxillary sinus, and zygoma in the maxilla.
(ii) Pathologic fracture.
Staging of MRONJ Treatment strategies
At risk No apparent necrotic bone in patients who have been treated 
with oral or intravenous bisphosphonates
No treatment indicated and patient 
education
Stage 0 No clinical evidence of necrotic bone but nonspecific clinical 
findings, radiographic changes, and symptoms
Systemic management, including use 
of pain medication and antibiotics
Stage 1 Exposed and necrotic bone or fistula that probes to bone in 
patients who are asymptomatic and have no evidence of infection
Antibiotic mouth rinse, clinical 
follow-up on a quarterly basis, 
patient education, and review 
of indications for continued 
bisphosphonate therapy
Stage 2 Exposed and necrotic bone or fistula that probes to bone 
associated with infection as evidenced by pain and erythema in 
the region of exposed bone with or without purulent drainage
Symptomatic treatment with oral 
antibiotics, oral bacterial mouth 
rinse, pain control, debridement 
to relieve soft tissue irritation, and 
infection control
Stage 3 Exposed and necrotic bone or a fistula that probes to bone in 
patients with pain, infection, and >1 of the following: exposed 
and necrotic bone extending beyond the region of alveolar bone 
(i.e., inferior border and ramus in mandible, maxillary sinus, and 
zygoma in maxilla) resulting in pathologic fracture, extra-oral 
fistula, oral antral or oral nasal communication, or osteolysis 
extending to inferior border of the mandible or sinus floor
Antibacterial mouth rinse, 
antibiotic therapy and pain control, 
surgical debridement or resection 
for longer-term palliation of 
infection and pain
Table 1. Staging and treatment strategies.
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(iii) Extra-oral fistula.
(iv) Oral antral or oral nasal communication.
(v) Osteolysis extending to the inferior border of the mandible or sinus floor.
Figure 1. MRONJ (Stage 2). Intraoral examination. The necrotic bone with evidence of infection is exposed. The 
permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
Figure 2. Panoramic X-ray. The permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
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Figure 4. The resected specimen of the mandible. The permission to use the picture of this figure from the Ishiyaku 
Publisher, Inc. in Japan.
Figure 3. The segmental resection of the mandible is performed under general anesthesia. There is partial bone defect. 
The permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
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Figure 5. MRONJ (Stage 3). Intraoral examination. The necrotic bone with evidence of infection is exposed. The molar 
teeth are lost naturally. The permission to use the pictures of this figure from the Ishiyaku Publisher, Inc. in Japan.
Figure 6. Necrotic bone extending beyond the region of alveolar bone is exposed, and extra-oral fistula is appeared. The 
permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
Figure 7. The panoramic X-ray. Regions of osteosclerosis involving the alveolar bone of lost molar teeth are depicted. 
The permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
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Figure 8. MRONJ (Stage 3). Sequester is extended to maxillary sinus. Oral antral communication is made. The permission 
to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
Figure 9. The sequester and six teethes are removed under local anesthesia. The oral antral communication is made at 
the anterior part of defect. The permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
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Figure 10. The necrotic bone and infiltrating inflammatory cells. The stimulating micrograms are observed (HE staining: 
100×). The permission to use the picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
Figure 11. Actinomycetes stained with Grocott in the granulation tissue (Grocott staining). The permission to use the 
picture of this figure from the Ishiyaku Publisher, Inc. in Japan.
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6. Treatment strategies for MRONJ
6.1. Treatment goals
The treatment goals for patients at risk of developing or who have MRONJ are prioritization 
and support of continued cancer treatment in patients receiving intra venous antiresorptive 
and antiangiogenic therapy [5, 12]. Cancer patients can benefit greatly from the therapeutic 
effect from antiresorptive agents by controlling SREs.
Maintenance of patient quality of life (QOL) is done by relieving symptoms, including pain, 
pus discharge, and paresthesia, and by control of infection. Moreover, patient education and 
routine follow-up for oral health care are needed by dental expert.
6.2. Stage-specific treatment strategies
Therapeutic strategies based on MRONJ stages are summarized in Table 1 [5].
Treatment of MRONJ varies with the stages of the disease. However, regardless of the stage, 
the protocol must include treating dental and periodontal diseases, maintaining and improv-
ing oral health with antibacterial mouthwash, and systemically administering antibacterial 
agents. To ensure success with surgical treatment, the complete elimination of MRONJ lesions 
and closure of surgical wounds is critical, along with systemic administration of antibacterial 
agents. For patients with a history of malignant tumors, histopathological examination of all 
necrotic bones removed will be needed to exclude the possibility that excised MRONJ lesions 
are tumor metastases to the jaw [12].
1. At risk
These patients have no exposed bone and requirement of any treatment. They should 
be informed of the risks of developing to MRONJ.
2. Stage 0
These patients receive the treatment of symptomatic disease and conservative manage-
ment of caries and periodontal disease. Systemic management, including use of pain 
medication and antibiotics are indicated. These patients should be prevented of pro-
gression to a higher stage.
3. Stage 1
These patients are indicated with medical management of the use for oral antimicrobial 
rinses, such as chlorhexidine 0.12%. No immediate surgery is required.
4. Stage 2
These patients are indicated with oral antimicrobial rinses in combination with admin-
istrating antibiotic therapy. The debridement to relieve soft tissue irritation and infec-
tion control is needed.
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5. Stage 3
These patients are benefit from debridement, including resection, in combination with 
antibiotic therapy. Symptomatic patients with stage 3 may require resection and imme-
diate reconstruction with reconstruction plate or an obturator.
Regardless of the disease stage, mobile bony sequestra should be removed to facilitate soft tis-
sue healing. The extraction of symptomatic teeth within exposed necrotic bone should be con-
sidered because it is unlikely that the extraction will exacerbate the established necrotic process.
6.3. Treatment with parathyroid hormone (teriparatide)
Systemic administration of low doses of recombinant parathyroid hormone (teriparatide) has 
been shown to resolve ONJ symptoms and promote a cure. Japanese studies have also shown 
improved bone regeneration and healing in ONJ lesions with the use of teriparatide [24, 25]. 
It should also be noted that administration of teriparatide is contraindicated in patients with 
metastatic bone tumors, and its total dose and period of administration are restricted as well.
7. Risk factors for MRONJ
Proposed risk factors for MRONJ are listed in Table 2 [12]. Among these factors, invasive 
dental treatments, such as tooth extraction, dental implant, or apical/periodontal surgery, are 
definitive local risk factors for MRONJ.
7.1. Dental implants and MRONJ [12]
Recent reports suggested that dental implant procedures performed in patients with cancer or 
osteoporosis prior to treatment with BPs are not likely associated with subsequent occurrence 
of MRONJ, if oral health is appropriately managed. However, dental implant performed 
 during or after BP treatment is a potential risk factor for MRONJ [26, 27].
It is unknown whether dental implant is a risk factor in patients receiving denosumab. Implants 
are not advised for cancer patients who are receiving antiresorptive treatment, and  alternative 
dental measures are recommended. On the other hand, in patients with  osteoporosis, den-
tal implant may be performed in cases in which physicians and dentists agree that dental 
implants are essential for improving the systemic and oral health of patients [12].
7.2. Coadministered agents and MRONJ
Antiangiogenic agents and tyrosine kinase inhibitors, which are essentially administered as 
adjuvants in the treatment of cancer patients, have been shown to cause MRONJ, albeit very 
rarely, when used alone, or to increase the incidence of MRONJ when used concomitantly 
with BP or denosumab [28].
Medication-Related Osteonecrosis of the Jaw
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8. Prevention of MRONJ
To minimize the development of ONJ in patients at risk, regular dental examinations are 
encouraged. Oral hygiene should be improved and local infection is managed as early as 
 possible. The use of antibiotics before and after oral surgical procedures has been demon-
strated to lower the risk of ONJ [29, 30]. Antimicrobial mouth rinses may also be useful in 
lowering the risk of ONJ [30, 31].
All necessary oral surgeries in oncology patients should ideally be completed before the  initiation 
of high-dose antiresorptive therapy. For oncology patient requiring high-dose intravenous BPs 
1. Local
Invasive dental treatments including bone (e.g., tooth extraction, dental implants, apical/periodontal surgery)
Ill-fitting dentures and excessive bite force
Poor sanitation in the oral cavity, periodontal disease, and gingival abscess inflammatory disease, including apical 
periodontitis
Common site: mandible > maxilla, mandibular torus, palatal torus, and mylohyoid line torus
Root canal and orthodontic treatments are not considered to be risk factors
2. Antiresorptive agents
Nitrogen-containing bisphosphonates (BPs) > nonnitrogen-containing BPs
Denosumab
Drugs for malignant tumor > drug for osteoporosis
Drug for malignant tumor (Zometa, Aredia, Teiroc, Ranmark)
Drug for osteoporosis (Didronel, Fosamac, Bonalon, Actonel, Benet, Bonoteo, Recalbon, Bonbiba and Pralia)
Dose and administration period
3. Systemic
Cancer (breast, prostate, lung, renal and colon cancer, multiple myeloma, and other cancers)
Diabetes, rheumatoid arthritis, hypocalcemia, hypoparathyroidism, osteomalacia, vitamin D deficiency, renal 
dialysis, anemia, and Paget's disease of bone
4. Congenital
Single-nucleotide polymorphisms (SNPs) in MMP-2 and cytochrome P450-2C genes
5. Lifestyle
Smoking, drinking alcohol, and obesity
6. Coadministered agents
Anticancer agents, corticosteroid, and erythropoietin
Angiogenic inhibitors (e.g., thalidomide, sunitinib, and lenalidomide)
Tyrosine kinase inhibitors
Table 2. Risk factors for MRONJ.
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or high-dose denosumab, dental radiographs should be completed before medication begins. 
Any invasive dental procedure including dental extractions or implants should ideally be com-
pleted before the initiation of antiresorptive therapy. Nonurgent procedures should be delayed 
if necessary. If ONJ develops, it is recommended that the antiresorptive drug therapy should be 
withheld until soft tissue closure with a well-epithelialized mucosa is achieved [32].
There is currently no evidence that interruption of drug therapy in patients requiring 
dental procedures reduces the risk of ONJ or the progression of the disease [29]. (BPs) 
that have long-term skeletal retention and cessation for weeks or months may not impact 
remodeling significantly. However, BPs do have increased skeletal uptake at the sites of 
local bone injury, and withholding BP therapy following oral surgery may be of use in 
reducing the local deposition in the mandible and maxilla after oral surgery. In individu-
als with significant risk factors for ONJ, including oncology patients on high-dose antire-
sorptive therapy as well as those individuals with multiple risk factors for ONJ, it may be 
of benefit to withhold BP or denosumab therapy following oral surgery until soft tissue 
healing occurs [32].
In determining the suitability if drug interruption, it is necessary to weigh the risks of ONJ 
with the risk of skeletal-related events in oncology patients and the risk of fracture in those 
with osteoporosis. The decision to hold therapy should be jointly made between the oral 
surgeon and the physician treating the underlying osteoporosis. Patients with  osteoporosis 
receiving BP or denosumab may continue with therapy if a dental procedure including 
extraction and implant surgery is required [4]. The decision to continue or hold antiresorp-
tive therapy should be made by the dental health provider in consultation with the patient’s 
physician [32].
8.1. Dental treatments and discontinuation of antiresorptive therapy
8.1.1. Dental treatments in patients who are to receive antiresorptive therapy
Before initiation of antiresorptive therapy, it is wise to request that patients visit a dentist for 
control of oral health to prevent the occurrence of ONJ. Ideally, all dental treatments should 
be completed 2 weeks before starting antiresorptive treatment. However, in the event that 
antiresorptive treatment cannot be delayed due to progression of bone metastases or high risk 
of fracture, administration of antiresorptive agents in parallel with dental treatments may be 
acceptable. During antiresorptive treatment, patients should be instructed by physicians to 
adhere to routine dental visits for oral examination [12].
8.1.2. Dental treatments in patients receiving antiresorptive agents
1. Discontinuation of BPs before starting dental treatment
There is a considerable controversy around the question of whether discontinuation 
(drug holiday) of BPs for a certain period of time before invasive dental treatment 
is  effective in preventing or reducing occurrence of BRONJ. A BP drug holiday be-
fore starting  invasive dental treatment is not logically supported from background 
 information [12]. The  American Association of Oral and Maxillofacial (AAOMS) and 
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other groups have described an increased incidence of BRONJ who were treated with 
BPs for longer than 4 years. From these results, AAOMS recommended that, for patients 
receiving antiresorptive therapy for longer than 4 years and who have low fracture 
risk but potentially high risk for BRONJ, discontinuation of antiresorptive treatment 
for approximately 2 months before invasive dental treatment should be considered, in 
consultation with the physician [5]. Thus, no consensus has yet been reached regarding 
whether a BP drug holiday before invasive dental treatment is appropriate and neces-
sary for prevention of BRONJ [12].
2. Suggested dental treatment in patients with cancer and osteoporosis who are receiving BPs
Dental experts will need to educate patients on the importance of daily oral sanitation, 
including how to clean the oral cavity after each meal and rinse their mouths with anti-
bacterial mouthwash. Subsequently, dentists begin conservative dental treatment with-
out discontinuation of BPs. In the case that invasive dental treatment such as removal of 
the teeth responsible for BRONJ is inevitable, however, antibacterial agents will be ad-
ministered to the patients in advance, and invasive dental treatments should be restricted 
to the minimum extent and area possible to avoid discontinuation of BP treatment [12].
3. Suggested dental treatment in patients with cancer and osteoporosis who are receiving 
denosumab
For cancer patients with bone metastases, studies have found that the benefits of denosumab 
are highly superior to those of zoledronic acid [11]. The incidence of DRONJ and BRONJ, 
however, was found to be similar in patients with cancer [3]. Similar to case of patients treated 
with BPs, dentists perform conservative dental treatment without drug holiday. Invasive den-
tal treatments, if inevitable, can be conducted without a drug holiday following appropriate 
infection control. Given that denosumab is administered to osteoporotic patients once every 6 
months and the half-life of denosumab is approximately 1 month, there is an ample window 
of time within the 6-month interval to plan for dental treatments [12].
4. Discontinuation of antiresorptive therapy after invasive dental treatment
Antiresorptive agents may interfere with the healing of surgical wounds, especially 
epithelialization [33]. The decision to continue or discontinue antiresorptive treatment 
must be made jointly by the physician and dentist based on fracture risk, and the status 
of healing of surgical wounds in the oral cavity.
5. Timing of resumption of antiresorptive therapy
The time at which to resume antiresorptive administration after a drug holiday is dependent 
on the balance between the healing of surgical wounds and control of the primary disease. 
If fracture risk or bone metastasis is well-controlled, resumption of antiresorptive treatment 
is recommended approximately 2 months after invasive dental procedure, when the dam-
aged alveolar bones are expected to have healed. However, if fracture risk is high or bone 
metastasis progresses during the drug holiday and resumption of antiresorptive therapy is 
urgent, it may resume antiresorptive drug with no sign of infection around surgical wounds 
and epithelialization of the surgical site at 2 weeks after invasive dental treatment, when 
epithelialization of the surgical site is almost complete, may be the earliest possibility [12].
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9. Case report of the patient of brain abscesses caused by MRONJ [34]
Reports of brain abscesses caused by MRONJ are very rare. The case of a 76-year-old man 
with terminal-stage prostatic carcinoma and a brain abscess caused by MRONJ at the maxilla 
with conscious loss is presented here. The zoledronic acid and denosumab were administered 
for bone metastasis. In the case of maxillary, MRONJ spreads beyond the maxillary sinus 
into the ethmoid sinus and into the brain. For the brain abscess, an antibiotic regimen based 
on ceftriaxone and metronidazole and a sequestrectomy contributed to a successful outcome 
(Figures 12–15).
Figure 12. Intra-oral examination. The 17 was lost naturally 2 months from the first visit and sequester was revealed. The 
sequester expanded in 8 months from socket.
Figure 13. Preoperative CT. Abscess formation is revealed in right maxillary sinus.
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Figure 15. MRI (T2WI) after conscious lost in ER. Right frontal lobe abscess is depicted.
Figure 14. CT after conscious lost in ER. The absorption image in right frontal lobe is revealed.
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10. Conclusion
Medication-related osteonecrosis of the jaw (MRONJ) is a common side effect of  antiresorptive 
drugs, which are administered to cancer patients for bone metastasis, multiple myeloma, and 
osteoporosis. All necessary oral surgeries in oncology patients should ideally be completed 
before the initiation of high-dose antiresorptive therapy, and to minimize the development of 
ONJ in patients at risk, regular dental examinations are encouraged. Oral hygiene should be 
improved and local infection should be managed as early as possible.
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